Patent classifications
A61K49/0002
PSMA-TARGETED PAMAM DENDRIMERS FOR SPECIFIC DELIVERY OF IMAGING, CONTRAST AND THERAPEUTIC AGENTS
Prostate-specific membrane antigen (PSMA)-targeted PAMAM dendrimers (G4-PSMA) and their use for imaging or treating PSMA-expressing tumors or cells are disclosed.
SYNTHESIS OF WATER-SOLUBLE THIOLATE-PROTECTED GOLD NANOPARTICLES OF UNIFORM SIZE AND CONJUGATES THEREOF
Methods of synthesizing water-soluble thiolate-protected gold nanoparticles of uniform size and conjugates thereof are disclosed. In particular, the invention relates to a method of synthesizing homogeneous, water-soluble gold nanoparticles by using a modified Brust procedure and methods of conjugating them. Gold nanoparticles, produced by the methods of the invention, are useful in various therapeutic and imaging applications where the use of gold nanoparticles having uniform structural and optical properties is desired.
Therapeutic inhibitor for EBV-associated tumor with tailor responsive optical imaging
This invention provides a nucleus-permeable small-molecule inhibitor, L.sub.2P.sub.4 (where L.sub.2 is 4-(4-(Diethylamino)styryl)-N-carboxymethylpyridinium chloride and P.sub.4 is an amino acid sequence comprising CAhxYFMVFGGRrRK and they were coupled through amide bond) and synthesis thereof, which effectively targets the dimerization interface of EBNA1, a critical process for the growth of EBVs and the associated tumors. The present invention also provides method of treating and imaging EBV-associated cancers.
Chemically-linked nanoparticles
Provided herein are compositions and methods of preparing nanoparticle aggregates.
Imaging beta-amyloid peptides aggregation
The present invention is in the field of pharmaceuticals and chemical industries. In particular, one aspect of the present invention relates to methods for labeling, imaging and detecting the beta-amyloid (Aβ) peptides, oligomers, and fibrils in vitro and in vivo via magnetic resonance and florescence imaging by using modified carbazole-based fluorophores. A further aspect of the present invention relates to a method of reducing and preventing aggregation of beta-amyloid peptides for Alzheimer's disease (AD) as well as of treating and/or preventing Alzheimer's disease by using the modified carbazole-based fluorophore. The modified carbazole-based fluorophore according to an embodiment of the present invention is prepared by conjugating a carbazole-based fluorophore with magnetic nanoparticles to form a conjugate which is permeable to blood brain barrier of a subject being introduced therewith.
Two-dimensional (2D) bismuth nanocomposite, and preparation method and use thereof
The disclosure relates to a two-dimensional (2D) bismuth nanocomposite, and a preparation method and use thereof, and belongs to the field of nanobiotechnology. The 2D bismuth nanocomposite of the disclosure is an ultra-thin bismuth nanosheet that is loaded with platinum nanoparticles and modified with indocyanine green (ICG) and surface targeting polypeptide Ang-2. The 2D bismuth nanocomposite Bi@Pt/ICG-Ang2 of the disclosure can not only realize the targeted photothermal and photodynamic combination therapy for tumors, but also realize the dual-mode imaging combining CT and fluorescence imaging.
Antibodies for molecular imaging of vulnerable plaques in atherosclerosis
Antibodies for molecular imaging of vulnerable plaques in atherosclerosis Antibody specifically binding to atherosclerosis lesions for in vivo imaging and methods for in vivo imaging of atherosclerosis lesions in a patient.
NON-LITHOTRIPSIC KIDNEY-STONE THERAPY
One aspect of the present invention relates to a method of using peristalsis to force a polymer plug through a mammalian lumen, thereby removing any calculi and/or calculi fragments present in the lumen. In one embodiment, the method is used as an alternative to conventional lithotripsy. In another embodiment, the method is used in conjunction with lithotripsy, thereby removing the small calculi fragments that result from such procedures.
Photoacoustic catheter for functional-imaging-based ablation monitoring
Functional imaging for localization in biological tissue entails measuring a response in the tissue (240) to electromagnetic radiation. A catheter (200) for real-time monitoring of cardiac ablation is employed to distinguish a hemorrhage zone (232) from the sandwiching necrotic and healthy tissue, or to distinguish exogenous photoacoustic contrast agent from bordering native tissue. A pair of wavelengths is selected for differential absorption (244) of the radiation in, correspondingly, the hemorrhage zone or where the contrast agent exists, and relatively similar absorption elsewhere. Near infrared laser or LED light may be used photoacoustically to serially acquire (S310, S320) the two datasets to be compared, each representative of a time waveform. Alternatively, acquisition is for a pair of wavelength bands of microwave-induced thermoacoustic data. In either case, the members of the dataset pair are combined (110, 122) by subtraction or division to effect the piece-wise cancellation/enhancement for display (218) of the resulting signal in real time.
Imaging fiducial markers and methods
An implantable tissue marker incorporates a contrast agent sealed within a chamber in a container formed from a solid material. The contrast agent is selected to produce a change, such as an increase, in signal intensity under magnetic resonance imaging (MRI). An additional contrast agent may also be sealed within the chamber to provide visibility under another imaging modality, such as computed tomographic (CT) imaging or ultrasound imaging.